Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Top Page
Y-Mabs Therapeutics
(NASDAQ:YMAB)
46Neutral
Positive Factors
Future Prospects
Investors willing to wait for the pipeline to mature will be well rewarded, leading to the reiteration of the Buy rating.
Research and Development
Positive data is expected from Part A of GD2-SADA's Ph1 study, which will include details about optimal dosing intervals.
Sales Performance
DANYELZA's 4Q24 sales represent a ~32% increase vs. 3Q24.
Negative Factors
Financial Performance
Y-mAbs recorded a 4Q24 net loss of $0.15 per share compared to a previously forecasted net loss of $0.04 per share.
Market Competition
Danyelza continues to face headwinds from patient competition, including due to competing therapies on the market and ongoing clinical trials.
Revenue Guidance
Flat to down FY25 revenue guidance of $75M - $90M triggered a negative stock reaction.
Y-Mabs Therapeutics (YMAB) vs. S&P 500 (SPY)
Market Cap
$203.48M
Dividend YieldN/A
Average Volume (3M)347.83K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue Growth3.38%
EPS Growth-36.40%
CountryUS
Employees104
SectorHealthcare
Sector Strength62
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,218,178
10 Day Avg. Volume332,708
30 Day Avg. Volume347,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.58
Price to Cash Flow (P/CF)-30.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.70Price Target Upside258.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Y-Mabs Therapeutics Business Overview & Revenue Model
Company DescriptionY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
How the Company Makes MoneyY-Mabs Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by bringing its drug candidates to market, which involves obtaining regulatory approvals, manufacturing the drugs, and distributing them through various healthcare channels. In addition to direct sales of their approved products, Y-Mabs may enter into strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or market its products, which can provide upfront payments, milestone payments, and royalties. Furthermore, the company may receive government grants or incentives for developing treatments for rare diseases, which can contribute to its revenue stream.
Y-Mabs Therapeutics Financial Statement Overview
Summary
Y-Mabs Therapeutics shows strong revenue growth and a solid equity position, yet profitability and cash flow remain significant challenges. The biotech industry demands high R&D investments, impacting financial performance. The company's balance sheet stability is overshadowed by ongoing operational losses and negative cash flow.Income Statement
Y-Mabs Therapeutics has shown revenue growth over recent years, with total revenue increasing from $20.75 million in 2020 to $87.68 million in 2024. However, the company is still facing significant challenges with profitability. The EBIT and EBITDA margins remain negative, indicating ongoing operational losses. The net profit margin is also negative, highlighting the unprofitable nature of the business at present.45
Neutral
Balance Sheet
The company maintains a strong equity position with a low debt-to-equity ratio of 0.009 in 2024, suggesting limited financial leverage risk. However, the return on equity remains negative due to net losses, and the equity ratio is robust, reflecting financial stability. The liquidity position, with substantial cash reserves, supports operational needs despite losses.60
Neutral
Cash Flow
Operating cash flow remains negative, indicating cash consumption from operations. Free cash flow has improved slightly but is still negative, showing reliance on financing activities. The operating cash flow to net income ratio suggests continued cash burn, posing challenges to sustainability without external funding.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 87.69M | 84.82M | 65.27M | 34.90M | 20.75M | Gross Profit |
| 72.43M | 73.40M | 57.70M | 32.38M | 18.55M | EBIT |
| -31.20M | -25.67M | -94.81M | -115.43M | -119.94M | EBITDA |
| -31.20M | -24.94M | -94.73M | -54.49M | -119.54M | Net Income Common Stockholders |
| -29.67M | -21.43M | -96.33M | -56.34M | -118.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 67.23M | 78.64M | 105.76M | 181.56M | 114.63M | Total Assets |
| 119.90M | 127.87M | 141.46M | 212.78M | 132.05M | Total Debt |
| 820.00K | 1.42M | 1.77M | 3.63M | 3.98M | Net Debt |
| -66.41M | -77.22M | -104.00M | -177.93M | -110.66M | Total Liabilities |
| 27.90M | 26.88M | 32.23M | 32.68M | 26.21M | Stockholders Equity |
| 92.00M | 100.98M | 109.22M | 180.11M | 105.84M |
| Cash Flow | Free Cash Flow | |||
| -15.71M | -27.23M | -75.92M | -103.52M | -91.41M | Operating Cash Flow |
| -15.71M | -27.23M | -75.92M | -102.56M | -91.23M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 61.04M | -2.79M | Financing Cash Flow |
| 4.31M | 100.00K | 84.00K | 108.31M | 2.00M |
Y-Mabs Therapeutics Technical Analysis
Negative
4.66
Price Trends
5.45
Negative
7.51
Negative
10.31
Negative
Market Momentum
-0.27
Negative
36.51
Neutral
23.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YMAB, the sentiment is Negative. The current price of 4.66 is below the 20-day moving average (MA) of 4.83, below the 50-day MA of 5.45, and below the 200-day MA of 10.31, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 36.51 is Neutral, neither overbought nor oversold. The STOCH value of 23.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YMAB.
Y-Mabs Therapeutics Risk Analysis
Y-Mabs Therapeutics disclosed 76 risk factors in its most recent earnings report. Y-Mabs Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Y-Mabs Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $224.09M | ― | -43.28% | ― | -3.92% | -18.67% | |
50 Neutral | $193.10M | ― | -170.97% | ― | -12.80% | 28.80% | |
49 Neutral | $213.07M | ― | -20.21% | ― | -8.92% | 31.98% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $203.48M | ― | -30.74% | ― | 3.38% | -36.40% | |
39 Underperform | $203.56M | ― | -59.51% | ― | 40.16% | -2.76% | |
31 Underperform | $144.14M | ― | -30.28% | ― | ― | -140.77% |
* Healthcare Sector Average
Performance Comparison
YMAB
Y-Mabs Therapeutics
4.66
-9.90
-67.99%
ANIK
Anika Therapeutics
15.05
-10.96
-42.14%
CRDF
Cardiff Oncology
2.87
-2.80
-49.38%
NGNE
Neurogene
9.67
-32.97
-77.32%
NVRO
Nevro Corp
5.84
-7.37
-55.79%
OM
Outset Medical
11.07
-18.03
-61.96%
Y-Mabs Therapeutics Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: -10.21% | Next Earnings Date: May 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive achievements, particularly in international revenue growth, radiopharmaceutical platform progress, and strong financial positioning. However, these were balanced by challenges, including revenue decline in the U.S., increased net loss, and difficulties in patient enrollment for trials. The strategic realignment is expected to address some of these challenges.Highlights
DANYELZA Revenue Growth
Total DANYELZA net product revenues for the full year 2024 were $85.2 million, with a 5% increase in Q4 2024 revenue compared to Q4 2023, driven by strong international markets.
Radiopharmaceutical Platform Progress
Achieved proof of concept with the SADA PRIT platform in the GD2-SADA Phase I trial, with no dose-limiting toxicities and positive tumor targeting and binding.
Strong International Performance
Ex-U.S. DANYELZA revenues increased by 78% in Q4 2024 compared to Q4 2023, driven by launches in Western Asia and increased sales in Eastern Asia and Latin America.
Financial Position
Ended 2024 with $67.7 million in cash and cash equivalents, with an annual cash investment of $11.4 million, below stated guidance, supporting plans into 2027.
Business Realignment Strategy
Implemented a strategic realignment to focus on two distinct business units, DANYELZA and Radiopharmaceuticals, to accelerate development and capital efficiency.
Lowlights
U.S. DANYELZA Revenue Decline
U.S. DANYELZA net product revenues decreased by 12% in Q4 2024 compared to Q4 2023, primarily due to unfavorable price mix.
Increased Net Loss
Reported a net loss of $6.8 million in Q4 2024, compared to $1 million in Q4 2023, primarily driven by increased operating expenses and an unfavorable impact from foreign currency transactions.
Challenges in CD38 SADA Patient Enrollment
Difficulties in enrolling patients for the CD38-SADA Phase I trial, with challenges related to patient qualification and health status.
Increased Operating Expenses
Selling and general administrative expenses increased by $9.8 million for the year ended December 31, 2024, due in part to legal settlements and restructuring charges.
Company Guidance
During the Y-mAbs Therapeutics earnings call for Q4 and full year 2024, the company provided guidance for the first quarter and full year of 2025. They anticipate total net revenue for 2025 to be between $75 million and $90 million and expect Q1 2025 revenue to range from $18 million to $21 million. Operating expenses excluding cost of goods sold are projected to be between $116 million and $121 million for 2025. The company ended 2024 with $67.7 million in cash and cash equivalents and expects their resources to support operations into 2027. Y-mAbs reported 2024 total revenue of $87.7 million, with DANYELZA net product revenues of $85.2 million and a steady U.S. market share of 15%-17%. They also highlighted strong international sales growth, particularly in Western Asia, Eastern Asia, and Latin America. The company is advancing its SADA PRIT radiopharmaceutical platform, with plans to share additional data in Q2 2025.Y-Mabs Therapeutics Corporate Events
Business Operations and Strategy
Y-mAbs Therapeutics Updates on Business and Clinical Trials
Neutral
Jan 13, 2025
Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.
Business Operations and Strategy
Y-mAbs Therapeutics Announces Strategic Business Realignment
Neutral
Jan 10, 2025
Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on radiopharmaceuticals and DANYELZA. This realignment includes a workforce reduction of up to 13% and relocation of roles from Denmark to the U.S. to optimize resources. The restructuring is expected to incur expenses of up to $2.6 million, impacting financial results through early 2026. Despite these changes, Y-mAbs plans to continue advancing its SADA PRIT platform and DANYELZA’s commercial potential, with significant milestones anticipated in 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.